Edition:
United Kingdom

Allergan plc (AGN.N)

AGN.N on New York Stock Exchange

185.72USD
4:27pm GMT
Change (% chg)

$4.39 (+2.42%)
Prev Close
$181.33
Open
$181.00
Day's High
$186.05
Day's Low
$181.00
Volume
173,261
Avg. Vol
675,315
52-wk High
$256.78
52-wk Low
$160.09

Latest Key Developments (Source: Significant Developments)

European Commission Approves Amgen, Allergan's Mvasi
Thursday, 18 Jan 2018 

Jan 18 (Reuters) - Amgen Inc ::EUROPEAN COMMISSION APPROVES AMGEN AND ALLERGAN'S MVASI® (BIOSIMILAR BEVACIZUMAB) FOR THE TREATMENT OF CERTAIN TYPES OF CANCER.AMGEN INC - EUROPEAN COMMISSION HAS GRANTED MARKETING AUTHORIZATION FOR MVASI.  Full Article

Allergan PLC Reports 6.8 Pct Stake In Teva Pharmaceutical Industries As Of January 10, 2018
Friday, 12 Jan 2018 

Jan 12 (Reuters) - Allergan Plc ::ALLERGAN PLC REPORTS 6.8 PERCENT STAKE IN TEVA PHARMACEUTICAL INDUSTRIES LTD AS OF JANUARY 10, 2018 - SEC FILING‍​.ALLERGAN PLC HAD EARLIER REPORTED 9.9 PERCENT STAKE IN TEVA PHARMACEUTICAL INDUSTRIES LTD AS OF NOVEMBER 10, 2017 - SEC FILING‍​.  Full Article

‍Pershing Square announces management fee reduction related to Allergan settlement​
Wednesday, 10 Jan 2018 

Jan 9 (Reuters) - Pershing Square Holdings Ltd ::‍PERSHING SQUARE HOLDINGS, LTD. ANNOUNCES MANAGEMENT FEE REDUCTION RELATED TO ALLERGAN SETTLEMENT.‍SUBSTANTIALLY ALL OF LEGAL FEES RELATED TO ALLERGAN MATTER HAVE BEEN COVERED BY INSURANCE.‍ASSUMING SETTLEMENT FINALIZED BY COURT, WILL BE REDUCING MANAGEMENT FEES FOR ALL OF PERSHING SQUARE FUNDS WHICH INCURRED LITIGATION EXPENSE BY TOTAL OF $32.2 MLN.‍FEE REDUCTION WILL BE REALIZED IN EIGHT INSTALLMENTS OVER NEXT 8 QUARTERS BEGINNING WITH MANAGEMENT FEE PAYABLE ON APRIL 1, 2018.‍REDUCTION IN MANAGEMENT FEES NOT SIMPLY TIMING BENEFIT FOR INVESTORS AS EXISTING YEAR-END 2017 HIGH WATER MARKS WILL REMAIN UNCHANGED​​​.  Full Article

Allergan Provides Preliminary 2018 Outlook, Update On Teva Holding
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Allergan Plc ::ALLERGAN PROVIDES 2018 PRELIMINARY FINANCIAL OUTLOOK FOR SELECT INCOME STATEMENT CATEGORIES AND OTHER UPDATES.SEES 2018 GAAP NET REVENUE OF ABOUT $15 BILLION - $15.3 BILLION.SEES 2018 GAAP PERFORMANCE LOSS PER SHARE $0.84; SEES 2018 NON-GAAP PERFORMANCE EARNINGS PER SHARE GREATER THAN OR EQUAL TO $15.25.FY2018 EARNINGS PER SHARE VIEW $15.80, REVENUE VIEW $15.61 BILLION -- THOMSON REUTERS I/B/E/S.SEES NO GENERIC ENTRY FOR RESTASIS PRIOR TO Q2 2018.SEES ONGOING COST REDUCTIONS OF $300 MILLION – $400 MILLION IN 2018 FROM FISCAL 2017 NON-GAAP OPERATING EXPENSES.ANTICIPATES FUTURE IMPACT OF TAX CUT AND JOBS ACT TO BE BROADLY NEUTRAL TO CO'S NON-GAAP EFFECTIVE TAX RATE OVER TIME.CONTINUES TO "PRUDENTLY DIVEST" ITS REMAINING HOLDING IN SECURITIES OF TEVA.PLANS TO SELL REMAINING POSITION IN TEVA IN 2018 THROUGH FORWARD SALE AGREEMENTS AND/OR OPEN MARKET SALES.SAYS "WE FACE LOSS OF EXCLUSIVITY REVENUE HEADWINDS IN 2018".  Full Article

Ironwood Pharmaceuticals Sees U.S. Net Sales Of Linzess Of About $700 Million‍​ For FY Ended Dec 31, 2017
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Ironwood Pharmaceuticals Inc ::IRONWOOD PHARMACEUTICALS INC - EXPECTED U.S. NET SALES OF LINZESS (LINACLOTIDE) OF ABOUT $700 MILLION‍​ FOR FY ENDED DEC 31, 2017.IRONWOOD PHARMACEUTICALS - ‍EXPECTED IRONWOOD REVENUE FROM LINACLOTIDE API SALES TO ASTELLAS OF MORE THAN $100 MILLION FROM JAN 1, 2017 TO DEC 31, 2019​.IRONWOOD PHARMACEUTICALS- EXPECTED REVENUE CAGR FROM THE LINZESS U.S. COLLABORATION WITH ALLERGAN OF ABOUT 75% FOR YEAR ENDED DEC 31, 2014 TO 2017.IRONWOOD PHARMACEUTICALS- EXPECTED LINZESS U.S. NET SALES CAGR OF GREATER THAN 30% FOR YEAR ENDED DEC 31, 2014 TO YEAR ENDED DECEMBER 31, 2017.  Full Article

Total Face Group Receives Notification Of Zeltiq Aesthetics Inc & Lumenis' Contract Termination
Thursday, 4 Jan 2018 

Jan 4 (Reuters) - Total Face Group Ltd ::RECEIVED OFFICIAL NOTIFICATION THAT CONTRACT BETWEEN ZELTIQ AESTHETICS INC AND LUMENIS BEEN TERMINATED.LUMENIS' RIGHTS TO DISTRIBUTE, TOGETHER WITH ALL REGULATORY RESPONSIBILITIES, HAS CEASED WITH EFFECT FROM DEC 31ST 2017.FROM JAN. 1, ALLERGAN AUSTRALIA TO TAKE OVER FULL RESPONSIBILITY FOR REGISTRATION, PROMOTION, SALES FOR COOLSCULPTING BUSINESS.  Full Article

Allergan Intends To Eliminate Over 1,000 Currently Filled Positions
Wednesday, 3 Jan 2018 

Jan 3 (Reuters) - Allergan Plc ::SAYS ‍ANNOUNCED TO GLOBAL WORKFORCE SPECIFIC EMPLOYMENT REDUCTIONS, OTHER COST-CUTTING ACTIONS BEING TAKEN, CONSISTENT WITH NOV ANNOUNCEMENT​.SAYS COMPANY INTENDS TO ELIMINATE OVER 1,000 CURRENTLY FILLED POSITIONS.SAYS IN ADDITION, COMPANY WILL ELIMINATE APPROXIMATELY 400 OPEN POSITIONS‍​ - SEC FILING.SAYS DUE TO EXPECTED LOSS OF EXCLUSIVITY OF SEVERAL KEY REVENUE-GENERATING PRODUCTS IN 2018, CO OPTIMIZING, RESTRUCTURING OPERATIONS IN EARLY 2018​.SAYS OPERATING EXPENSE SAVINGS FROM RESTRUCTURING EXPECTED TO BE $300 MILLION TO $400 MILLION VERSUS FISCAL 2017.SAYS ‍EXPECTS TO INCUR RESTRUCTURING COSTS OF ABOUT $125 MILLION, PRIMARILY DUE TO SEVERANCE, MAJORITY OF IT TO BE RECORDED IN Q4 ENDED DEC 31.  Full Article

Allergan Says In Connection With Internal Reorganization, Forest Laboratories Merged With And Into Allergan Sales
Tuesday, 2 Jan 2018 

Jan 2 (Reuters) - Allergan Plc ::ALLERGAN SAYS IN CONNECTION WITH INTERNAL REORGANIZATION, FOREST LABORATORIES LLC MERGED WITH AND INTO ALLERGAN SALES LLC- SEC FILING.  Full Article

Pershing Square Announces Agreement To Settle Lawsuits Related To Allergan
Friday, 29 Dec 2017 

Dec 29 (Reuters) - Pershing Square Holdings Ltd ::PERSHING SQUARE ANNOUNCES AGREEMENT IN PRINCIPLE TO SETTLE LAWSUITS RELATED TO ALLERGAN.VALEANT ORIGINALLY AGREED TO PAY 60% SETTLEMENT COST; VALEANT, CO HAD DIFFERENT VIEWS ON DESIRABILITY,TIMING OF SETTLING CASE.PERSHING SQUARE HAD PREVIOUSLY SET ASIDE $75 MILLION IN LEGAL RESERVES RELATED TO THE ALLERGAN CASE.INCREMENTAL COST OF SETTLING LITIGATION WILL REDUCE PSH'S & PRIVATE FUNDS' PERFORMANCE AND NET ASSET VALUE BY 132 BASIS POINTS.  Full Article

Allergan Acknowledges Appeals Court Decision For Combigan
Friday, 22 Dec 2017 

Dec 22 (Reuters) - Allergan Plc ::ALLERGAN ACKNOWLEDGES APPEALS COURT DECISION FOR COMBIGAN®.SAYS ‍CO EXPECTS TO FILE PETITIONS FOR REHEARING AND/OR REHEARING EN BANC OF APPEALS COURT DECISION WITHIN 30 DAYS​.ALLERGAN - DOESN'T BELIEVE COURT'S INJUNCTION PREVENTING FINAL APPROVAL, LAUNCH OF SANDOZ PRODUCT WILL BE LIFTED PRIOR TO DECISION ON CO'S PETITIONS.ALLERGAN - APPEALS COURT RULING WILL NOT RESULT IN MARKET FORMATION FOR GENERIC COMBIGAN PRODUCT.  Full Article

BRIEF-European Commission Approves Amgen, Allergan's Mvasi

* EUROPEAN COMMISSION APPROVES AMGEN AND ALLERGAN'S MVASI® (BIOSIMILAR BEVACIZUMAB) FOR THE TREATMENT OF CERTAIN TYPES OF CANCER